A new study finds halving standard steroid dose treats most acute GVHD just as well; could limit dangerous side effects
Feb. 19, 2015
| By Dr. Rachel Tompa / Fred Hutch News Service
Up to 70 percent of transplant patients develop acute graft-vs.-host disease. Standard treatment for GVHD, the steroid prednisone, carries its own host of side effects. Fred Hutch's Dr. Marco Mielcarek led a new study testing lower doses of prednisone in patients with acute GVHD -- with promising results.
NHLBI grant will expand research into protective mechanisms of statins against severe acute graft-vs.-host disease in transplant patients
May 16, 2011
| By Dean Forbes
The Fred Hutchinson Cancer Research Center Clinical Research Division’s Dr. Marco Mielcarek has received $2.2 million from the National Institutes of Health’s National Heart, Lung and Blood Institute to continue research on whether statin treatment is effective at reducing the risk of graft-vs.-host disease in patients receiving an allogeneic stem cell transplant. While statins are a class of drugs for treating high cholesterol, they also have immune-modulating effects.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.